Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
133M
-
Shares change
-
+88M
-
Total reported value, excl. options
-
$303M
-
Value change
-
+$214M
-
Put/Call ratio
-
0.4
-
Number of buys
-
55
-
Number of sells
-
-29
-
Price
-
$2.27
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2025
100 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q2 2025.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 133M shares
of 166M outstanding shares and own 80.52% of the company stock.
Largest 10 shareholders include VR ADVISER, LLC (14M shares), TANG CAPITAL MANAGEMENT LLC (11.1M shares), VANGUARD GROUP INC (9.38M shares), FMR LLC (9.24M shares), ORBIMED ADVISORS LLC (8.46M shares), Point72 Asset Management, L.P. (8.08M shares), Commodore Capital LP (7.69M shares), PERCEPTIVE ADVISORS LLC (6.99M shares), FRANKLIN RESOURCES INC (5.77M shares), and Vivo Capital, LLC (5.77M shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.